Evidence map›Paper›PMID 34751250›Full record

ReviewBeni-Suef University journal of basic and applied sciences2021

Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent.

Vijay K Patel, Ekta Shirbhate, Preeti Patel, Ravichandran Veerasamy, Prabodh C Sharma, Harish Rajak

Open access · diamondAbstract readReview
In one paragraph

Review in Beni-Suef University journal of basic and applied sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Promising Potential of Curcumin and Related Compounds for Antiviral Drug Discovery.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Molecules (Basel, Switzerland) · 2023
    Article
  14. Article
  15. Article
  16. Review
  17. Immune-based therapeutic approaches in COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  18. Article
  19. Repurposing of Chemotherapeutics to Combat COVID-19.Current topics in medicinal chemistry · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Vijay K PatelInstitute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur, C.G. 495 009 India.
Ekta ShirbhateInstitute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur, C.G. 495 009 India.
Preeti PatelInstitute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur, C.G. 495 009 India.
Ravichandran VeerasamyFaculty of Pharmacy, AIMST University, 08100 Semeling, Bedong, Kedah Darul Aman Malaysia.
Prabodh C SharmaDepartment of Pharmaceutical Chemistry, Delhi Pharmaceutical Sciences and Research University, MB Road, Pushp Vihar, New Delhi, 110 017 India.
Harish RajakInstitute of Pharmaceutical Sciences, Guru Ghasidas University, Bilaspur, C.G. 495 009 India.ORCID 0000-0003-2008-2827
Guru Ghasidas Vishwavidyalaya · INAIMST University · MYDelhi Pharmaceutical Science and Research University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe World Health Organization (WHO) announced the COVID-19 occurrence as a global pandemic in March 2020. The treatment of SARS-CoV-2 patients is based on the experience gained from SARS-CoV and MERS-CoV infection during 2003. There is no clinically accepted therapeutic drug(s) accessible yet for the treatment of COVID-19. MAIN BODY: Corticosteroids, i.e., dexamethasone, methylprednisolone, hydrocortisone and prednisone are used alone or in combination for the treatment of moderate, severe and critically infected COVID-19 patients who are hospitalized and require supplemental oxygen as per current management strategies and guidelines for COVID-19 published by the National Institutes of Health. Corticosteroids are recorded in the WHO model list of essential medicines and are easily accessible worldwide at a cheaper cost in multiple formulations and various dosage forms. Corticosteroid can be used in all age group of patients, i.e., children, adult, elderly and during pregnancy or breastfeeding women. Corticosteroids have potent anti-inflammatory and immunosuppressive effects in both primary and secondary immune cells, thereby reducing the generation of proinflammatory cytokines and chemokines and lowering the activation of T cells, monocytes and macrophages. The corticosteroids should not be used in the treatment of non-severe COVID-19 patients because corticosteroids suppress the immune response and reduce the symptoms and associated side effects such as slow recovery, bacterial infections, hypokalemia, mucormycosis and finally increase the chances of death.

conclusionIntensive research on corticosteroid therapy in COVID-19 treatment is urgently needed to elucidate their mechanisms and importance in contributing toward successful prevention and treatment approaches. Hence, this review emphasizes on recent advancement on corticosteroid therapy for defining their importance in overcoming SARS-CoV-2 pandemic, their mechanism, efficacy and extent of corticosteroids in the treatment of COVID-19 patients.

Indexed as

CorticosteroidsCOVID-19DexamethasoneHydrocortisoneMethylprednisolonePrednisone

Identifiers

PMID34751250
PMCPMC8567120
OpenAlexW3210653355

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.